STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio...
Hence then, the article about u s fda approves celltrion s steqeyma ustekinumab stba a biosimilar to stelara ustekinumab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) )
Also on site :
- Best-Selling Author’s Novel, Ranked ‘Readers’ Favorite Mystery and Thriller,’ Was Built on a Wild Premise
- Meta’s AI Is Delivering but Comes With a Hefty Price Tag .. PYMNTS.com
- Meta looks to report fastest revenue growth since 2021